<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38174926</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.</ArticleTitle><Pagination><StartPage>e0155823</StartPage><MedlinePgn>e0155823</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01558-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.01558-23</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) can induce severe neurological complications and even fatal encephalitis in children, and it has caused several large outbreaks in Taiwan since 1998. We previously generated VP1 codon-deoptimized (VP1-CD) reverse genetics (rg) EV-A71 viruses (rgEV-A71s) that harbor a high-fidelity (HF) 3D polymerase. These VP1-CD-HF rgEV-A71s showed lower replication kinetics <i>in vitro</i> and decreased virulence in an Institute of Cancer Research (ICR) mouse model of EV-A71 infection, while still retaining their antigenicity in comparison to the wild-type virus. In this study, we aimed to further investigate the humoral and cellular immune responses elicited by VP1-CD-HF rgEV-A71s to assess the potential efficacy of these EV-A71 vaccine candidates. Following intraperitoneal (i.p.) injection of VP1-CD-HF rgEV-A71s in mice, we observed a robust induction of EV-A71-specific neutralizing IgG antibodies in the antisera after 21 days. Splenocytes isolated from VP1-CD-HF rgEV-A71s-immunized mice exhibited enhanced proliferative activities and cytokine production (IL-2, IFN-γ, IL-4, IL-6, and TNF-α) upon re-stimulation with VP1-CD-HF rgEV-A71, as compared to control mice treated with adjuvant only. Importantly, administration of antisera from VP1-CD-HF rgEV-A71s-immunized mice protected against lethal EV-A71 challenge in neonatal mice. These findings highlight that our generated VP1-CD-HF rgEV-A71 viruses are capable of inducing both cellular and humoral immune responses, supporting their potential as next-generation EV-A71 vaccines for combating EV-A71 infection.IMPORTANCEEV-A71 can cause severe neurological diseases and cause death in young children. Here, we report the development of synthetic rgEV-A71s with the combination of codon deoptimization and high-fidelity (HF) substitutions that generate genetically stable reverse genetics (rg) viruses as potential attenuated vaccine candidates. Our work provides insight into the development of low-virulence candidate vaccines through a series of viral genetic editing for maintaining antigenicity and genome stability and suggests a strategy for the development of an innovative next-generation vaccine against EV-A71.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hsieh</LastName><ForeName>Wen-Sheng</ForeName><Initials>W-S</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chao</LastName><ForeName>Chiao-Hsuan</ForeName><Initials>C-H</Initials><Identifier Source="ORCID">0000-0003-0114-0948</Identifier><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Chun-Yu</ForeName><Initials>C-Y</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Dayna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sheng-Wen</ForeName><Initials>S-W</Initials><AffiliationInfo><Affiliation>National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ya-Fang</ForeName><Initials>Y-F</Initials><AffiliationInfo><Affiliation>National Mosquito-Borne Diseases Control Research Center, National Health Research Institutes, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chien-Chin</ForeName><Initials>C-C</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shun-Hua</ForeName><Initials>S-H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Li-Jin</ForeName><Initials>L-J</Initials><Identifier Source="ORCID">0009-0007-9395-6077</Identifier><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>J-R</Initials><Identifier Source="ORCID">0000-0002-4127-4046</Identifier><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>108-2321-B-006-012, 110-2320-B-006-031-MY3</GrantID><Agency>National Science and Technology Council (NSTC)</Agency><Country /></Grant><Grant><GrantID>NHRI IV-112-PP-12</GrantID><Agency>National Health Research Institutes (NHRI)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003062">Codon</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003062" MajorTopicYN="N">Codon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="Y">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="Y">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">codon-deoptimization</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">high-fidelity</Keyword><Keyword MajorTopicYN="N">reverse genetics virus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38174926</ArticleId><ArticleId IdType="pmc">PMC10804986</ArticleId><ArticleId IdType="doi">10.1128/jvi.01558-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jacobson MF, Baltimore D. 1968. Morphogenesis of poliovirus. I. Association of the viral RNA with coat protein. J Mol Biol 33:369–378. doi:10.1016/0022-2836(68)90195-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(68)90195-2</ArticleId><ArticleId IdType="pubmed">4302632</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips BA, Fennell R. 1973. Polypeptide composition of poliovirions, naturally occurring empty capsids, and 14S precursor particles. J Virol 12:291–299. doi:10.1128/JVI.12.2.291-299.1973</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.12.2.291-299.1973</ArticleId><ArticleId IdType="pmc">PMC356623</ArticleId><ArticleId IdType="pubmed">4355933</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B, Vriend G. 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317:145–153. doi:10.1038/317145a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/317145a0</ArticleId><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91–107. doi:10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S-C, Hsu Y-W, Wang H-C, Huang S-W, Kiang D, Tsai H-P, Wang S-M, Liu C-C, Lin K-H, Su I-J, Wang J-R. 2008. Appearance of intratypic recombination of enterovirus 71 in Taiwan from 2002 to 2005. Virus Res 131:250–259. doi:10.1016/j.virusres.2007.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2007.10.002</ArticleId><ArticleId IdType="pubmed">18036697</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. 2019. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci 26:75. doi:10.1186/s12929-019-0573-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, Jegathesan M, Anderson LJ. 2000. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31:678–683. doi:10.1086/314032</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen E-R, Hsu K-H, Twu S-J, Chen K-T, Tsai S-F, Wang J-R, Shih S-R. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341:929–935. doi:10.1056/NEJM199909233411301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Tseng H-W, Wang S-M, Wang J-R, Su I-J. 2000. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17:23–30. doi:10.1016/s1386-6532(00)00068-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1386-6532(00)00068-8</ArticleId><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-Y, Huang P-N, Huang Y-C, Yang S-L, Tsao K-C, Chiu C-H, Shih S-R, Lin T-Y. 2020. Emergence of genotype C1 enterovirus A71 and its link with antigenic variation of virus in Taiwan. PLoS Pathog 16:e1008857. doi:10.1371/journal.ppat.1008857</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008857</ArticleId><ArticleId IdType="pmc">PMC7521691</ArticleId><ArticleId IdType="pubmed">32936838</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S-C, Chang H-L, Yan T-R, Cheng Y-T, Chen K-T. 2007. An eight-year study of epidemiologic features of Enterovirus 71 infection in Taiwan. Am J Trop Med Hyg 77:188–191. doi:10.4269/ajtmh.2007.77.188</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2007.77.188</ArticleId><ArticleId IdType="pubmed">17620652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T-Y, Twu S-J, Ho M-S, Chang L-Y, Lee C-Y. 2003. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9:291–293. doi:10.3201/eid0903.020285</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0903.020285</ArticleId><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, Yang KD. 2002. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91:632–635. doi:10.1080/080352502760069016</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/080352502760069016</ArticleId><ArticleId IdType="pubmed">12162592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-M, Lei H-Y, Huang K-J, Wu J-M, Wang J-R, Yu C-K, Su I-J, Liu C-C. 2003. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188:564–570. doi:10.1086/376998</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. . 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024–2032. doi:10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. . 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370:818–828. doi:10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung M-C, Cho C-Y, Chen C-J, Lai C-C, Wu K-G. 2019. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial. Vaccine 37:5559–5566. doi:10.1016/j.vaccine.2019.07.096</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.096</ArticleId><ArticleId IdType="pubmed">31399275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, Chiu C-H, Lin C-Y, Chiu N-C, Chen P-Y, Le TTV, Le DN, Duong AH, Nguyen VL, Huynh TN, Truong HK, Phan TL, Nguyen TTT, Shih S-R, Huang C-G, Weng Y-J, Hsieh E-F, Chang S, Chen C, Tai I-C, Huang L-M. 2022. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 399:1708–1717. doi:10.1016/S0140-6736(22)00313-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00313-0</ArticleId><ArticleId IdType="pubmed">35427481</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y-H, Huang S-W, Hsieh W-S, Cheng C-K, Chang C-F, Wang Y-F, Wang J-R. 2019. Enterovirus A71 containing codon-deoptimized VP1 and high-fidelity polymerase as next-generation vaccine candidate. J Virol 93:e02308-18. doi:10.1128/JVI.02308-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02308-18</ArticleId><ArticleId IdType="pmc">PMC6580961</ArticleId><ArticleId IdType="pubmed">30996087</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Zhang C, Zhang R, Ren J, Chen S, Sui M, Zhou G, Dang D, Zhu J, Feng H, Xi Y, Yang H, Duan G. 2017. Pulmonary edema following central nervous system lesions induced by a non- mouse-adapted EV71 strain in neonatal BALB/c mice. Virol J 14:243. doi:10.1186/s12985-017-0911-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0911-5</ArticleId><ArticleId IdType="pmc">PMC5745784</ArticleId><ArticleId IdType="pubmed">29282065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji W, Sun T, Li D, Chen S, Yang H, Jin Y, Duan G. 2023. TBK1 and IRF3 are potential therapeutic targets in enterovirus A71-associated diseases. PLoS Negl Trop Dis 17:e0011001. doi:10.1371/journal.pntd.0011001</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0011001</ArticleId><ArticleId IdType="pmc">PMC9831319</ArticleId><ArticleId IdType="pubmed">36626364</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C. 2021. Cytokine regulation and function in T cells. Annu Rev Immunol 39:51–76. doi:10.1146/annurev-immunol-061020-053702</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-061020-053702</ArticleId><ArticleId IdType="pubmed">33428453</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenke N, Trimpert J, Merz S, Conradie AM, Wyler E, Zhang H, Hazapis O-G, Rausch S, Landthaler M, Osterrieder N, Kunec D. 2020. Mechanism of virus attenuation by codon pair deoptimization. Cell Rep 31:107586. doi:10.1016/j.celrep.2020.107586</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107586</ArticleId><ArticleId IdType="pubmed">32348767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. 2006. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 80:9687–9696. doi:10.1128/JVI.00738-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00738-06</ArticleId><ArticleId IdType="pmc">PMC1617239</ArticleId><ArticleId IdType="pubmed">16973573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogales A, Baker SF, Ortiz-Riaño E, Dewhurst S, Topham DJ, Martínez-Sobrido L. 2014. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 88:10525–10540. doi:10.1128/JVI.01565-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01565-14</ArticleId><ArticleId IdType="pmc">PMC4178899</ArticleId><ArticleId IdType="pubmed">24965472</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng BYH, Ortiz-Riaño E, Nogales A, de la Torre JC, Martínez-Sobrido L. 2015. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol 89:3523–3533. doi:10.1128/JVI.03401-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03401-14</ArticleId><ArticleId IdType="pmc">PMC4403387</ArticleId><ArticleId IdType="pubmed">25589652</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. 2015. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel) 3:320–343. doi:10.3390/vaccines3020320</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines3020320</ArticleId><ArticleId IdType="pmc">PMC4494348</ArticleId><ArticleId IdType="pubmed">26343190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. 2011. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine 29:9538–9543. doi:10.1016/j.vaccine.2011.09.124</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.124</ArticleId><ArticleId IdType="pubmed">22001122</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Hagan DT, Ott GS, De Gregorio E, Seubert A. 2012. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30:4341–4348. doi:10.1016/j.vaccine.2011.09.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.061</ArticleId><ArticleId IdType="pubmed">22682289</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. 2013. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 12:13–30. doi:10.1586/erv.12.140</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.12.140</ArticleId><ArticleId IdType="pubmed">23256736</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathinayake PS, Gayan Chathuranga WA, Lee H-C, Chowdhury MYE, Sung M-H, Lee J-S, Kim C-J. 2018. Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice. Arch Virol 163:2073–2083. doi:10.1007/s00705-018-3837-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-018-3837-3</ArticleId><ArticleId IdType="pubmed">29619599</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarepour M, Bhullar K, Montero M, Ma C, Huang T, Velcich A, Xia L, Vallance BA. 2013. The mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during Salmonella enterica serovar Typhimurium colitis. Infect Immun 81:3672–3683. doi:10.1128/IAI.00854-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00854-13</ArticleId><ArticleId IdType="pmc">PMC3811786</ArticleId><ArticleId IdType="pubmed">23876803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>